Skip to content

Twitter Linkedin Instagram

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: May 8, 2019

25 kg of GMP Monepantel from Elanco

News & Announcements 2019By Richard Mollard May 8, 2019

190508_GMP_25kg

Recent Articles

Appendix 3B – Exercise of Options
November 8, 2019
Progress in Recruitment for Phase II Trial in Dogs
November 4, 2019
Appendix 4C and Quarterly Update
November 1, 2019
31 October, Top 20 Shareholders
November 1, 2019

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

JP Equity Partners @jpequitypartner·

PharmAust Limited $PAA is currently recruiting for its Phase 2 trial in dogs with lymphoma. The trial will evaluate the drug MPL, which has shown promising anti-cancer results in previous Phase I studies in dogs and in humans with cancer. 🦠‍🔬 Article: https://t.co/OUcwA3mrVr

Reply on Twitter 1194782136877961216 Retweet on Twitter 11947821368779612162 Like on Twitter 11947821368779612167 Twitter 1194782136877961216

Copyright © 2019 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions